Literature DB >> 33031824

New role of TRPM4 channel in the cardiac excitation-contraction coupling in response to physiological and pathological hypertrophy in mouse.

Christophe Hedon1, Karen Lambert1, Nourdine Chakouri1, Jérôme Thireau1, Franck Aimond1, Cécile Cassan1, Patrice Bideaux1, Sylvain Richard1, Adèle Faucherre2, Jean-Yves Le Guennec1, Marie Demion3.   

Abstract

The transient receptor potential Melastatin 4 (TRPM4) channel is a calcium-activated non-selective cation channel expressed widely. In the heart, using a knock-out mouse model, the TRPM4 channel has been shown to be involved in multiple processes, including β-adrenergic regulation, cardiac conduction, action potential duration and hypertrophic adaptations. This channel was recently shown to be involved in stress-induced cardiac arrhythmias in a mouse model overexpressing TRPM4 in ventricular cardiomyocytes. However, the link between TRPM4 channel expression in ventricular cardiomyocytes, the hypertrophic response to stress and/or cellular arrhythmias has yet to be elucidated. In this present study, we induced pathological hypertrophy in response to myocardial infarction using a mouse model of Trpm4 gene invalidation, and demonstrate that TRPM4 is essential for survival. We also demonstrate that the TRPM4 is required to activate both the Akt and Calcineurin pathways. Finally, using two hypertrophy models, either a physiological response to endurance training or a pathological response to myocardial infarction, we show that TRPM4 plays a role in regulating transient calcium amplitudes and leads to the development of cellular arrhythmias potentially in cooperation with the Sodium-calcium exchange (NCX). Here, we report two functions of the TRPM4 channel: first its role in adaptive hypertrophy, and second its association with NCX could mediate transient calcium amplitudes which trigger cellular arrhythmias.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arrhythmias; Hypertrophy; Myocardial infarction; SOCE; TRPM4 channel

Year:  2020        PMID: 33031824     DOI: 10.1016/j.pbiomolbio.2020.09.006

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  5 in total

1.  Fibroblast growth factor homologous factors serve as a molecular rheostat in tuning arrhythmogenic cardiac late sodium current.

Authors:  Nourdine Chakouri; Sharen Rivas; Daniel Roybal; Lin Yang; Johanna Diaz; Allen Hsu; Ryan Mahling; Bi-Xing Chen; Josiah O Owoyemi; Deborah DiSilvestre; Dario Sirabella; Barbara Corneo; Gordon F Tomaselli; Ivy E Dick; Steven O Marx; Manu Ben-Johny
Journal:  Nat Cardiovasc Res       Date:  2022-05-16

2.  Upregulation of transient receptor potential melastatin 4 (TRPM4) in ventricular fibroblasts from heart failure patients.

Authors:  Jianlin Feng; Pengyu Zong; Jiajie Yan; Zhichao Yue; Xin Li; Chevaughn Smith; Xun Ai; Lixia Yue
Journal:  Pflugers Arch       Date:  2021-02-16       Impact factor: 3.657

3.  Differential effects of TRPM4 channel inhibitors on Guinea pig urinary bladder smooth muscle excitability and contractility: Novel 4-chloro-2-[2-(2-chloro-phenoxy)-acetylamino]-benzoic acid (CBA) versus classical 9-phenanthrol.

Authors:  John Malysz; Sarah E Maxwell; Georgi V Petkov
Journal:  Pharmacol Res Perspect       Date:  2022-08

Review 4.  Calcium and Heart Failure: How Did We Get Here and Where Are We Going?

Authors:  Natthaphat Siri-Angkul; Behzad Dadfar; Riya Jaleel; Jazna Naushad; Jaseela Parambathazhath; Angelia A Doye; Lai-Hua Xie; Judith K Gwathmey
Journal:  Int J Mol Sci       Date:  2021-07-09       Impact factor: 6.208

Review 5.  Pharmacological Modulation and (Patho)Physiological Roles of TRPM4 Channel-Part 2: TRPM4 in Health and Disease.

Authors:  Csaba Dienes; Zsigmond Máté Kovács; Tamás Hézső; János Almássy; János Magyar; Tamás Bányász; Péter P Nánási; Balázs Horváth; Norbert Szentandrássy
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.